Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech

Summary Ligand Pharmaceuticals (LGND) is reassessed after a ~10% loss since its last 'Buy' rating. The article focuses on LGND’s future prospects, emphasizing its key royalty producing assets. LGND is highlighted as a reliable midcap pharma with a high-growth business model. Investment thesis centers on its historically strong execution of its royalty-aggregation model. BlackJack3D/iStock via Getty Images This is my thirteenth Ligand ( LGND ) article, following my most recent 06/2026's "Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator " In Aggregator , I rated Ligand as a "Buy". It has This article was written by Out of Ignorance 7.79K Followers Follow Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences. Analyst’s Disclosure: I/we have a beneficial long position in the shares of LGND, GILD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I may buy shares in Ligand over the next 72 hours. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.